Plant Name: Eriodictyon californicum
Taxonomic Information:
Plant ID: NPO11318
Plant Latin Name: Eriodictyon californicum
Taxonomy Genus: Eriodictyon
Taxonomy Family: Namaceae
Plant External Links:
NCBI TaxonomyDB:
4132
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Unknown.
Geographical Distribution:
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.193E-11 | 2.598E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.494E-11 | 2.716E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.313E-10 | 7.145E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, XDH |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.389E-10 | 1.054E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.012E-10 | 1.364E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.286E-09 | 6.771E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.228E-08 | 6.458E-05 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.418E-07 | 2.289E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 8.143E-07 | 6.114E-04 | CYP19A1, CYP1A1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.709E-07 | 7.047E-04 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.768E-06 | 1.222E-03 | CYP1A1, CYP1A2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.797E-06 | 1.222E-03 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.417E-06 | 2.599E-03 | CYP1A2, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 6.037E-06 | 3.459E-03 | CBR1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 8.240E-06 | 4.601E-03 | CYP1A1, CYP1A2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.639E-10 | 8.351E-09 | CBR1, CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.069E-08 | 1.862E-07 | CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.286E-08 | 3.172E-07 | CBR1, CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.209E-06 | 4.354E-06 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.392E-06 | 7.065E-06 | CYP1A1, CYP1B1, CYP19A1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.969E-05 | 4.431E-05 | CBR1, CYP1A2, CYP1A1, CYP2C19, CYP19A1, XDH |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 8.381E-08 | 3.771E-07 | CA12, CA4, CA7 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 5.108E-04 | 9.185E-04 | CBR1, CYP2C19 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 5.613E-04 | 9.185E-04 | CYP1A2, CYP1A1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.108E-04 | 2.215E-04 | CYP1A2, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 6.323E-04 | 9.485E-04 | CYP1A2, CYP2C19 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.748E-06 | 7.065E-06 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
